Lexaria Bioscience (LEXX) EBITDA Margin (2017 - 2026)

Lexaria Bioscience has disclosed EBITDA Margin across 10 years of filings, most recently posting 7146.72% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 7146.72%, down 553266.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 2572.59% (down 76985.0% YoY), and the FY2025 annual result was 1693.15%, down 44064.0% from the prior year.
• EBITDA Margin came in at 7146.72% for Q1 2026 at Lexaria Bioscience, down from 1543.16% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 465.2% in Q1 2024 to a low of 7146.72% in Q1 2026.
• The 5-year median for EBITDA Margin is 2139.41% (2024), against an average of 2683.1%.
• Across the five-year window, EBITDA Margin jumped 1263767 bps in 2022 and sank 553266 bps in 2026, its largest moves.
• Lexaria Bioscience's EBITDA Margin stood at 1796.64% in 2022, then jumped by 57 bps to 776.68% in 2023, then slumped by 89 bps to 1471.74% in 2024, then declined by 5 bps to 1543.16% in 2025, then plunged by 363 bps to 7146.72% in 2026.
• The last three EBITDA Margin figures came in at 7146.72% (Q1 2026), 1543.16% (Q3 2025), and 2156.28% (Q2 2025), per Business Quant data.